Brent Is Above $101. Novorossiysk Is the Risk Wall Street Misprices.
Ukraine’s strike adds a different supply risk than US-Iran tensions, and the market is treating them as interchangeable.
A Pill Just Matched Injectable HAE Drugs in Phase 3
Pharvaris hit every endpoint and BCRX dropped 9%. The asymmetry now favors defined-risk positions on the incumbents.
Novartis Bought a Platform. The Lead Drug Just Failed. Now What?
The del-desiran miss raises a question large-cap pharma investors dodge: how much of a share price is pipeline hope, and…
Expedia and Booking’s Big Drop Is Not About Fuel Costs
When travel sells off with no company news, crude is hitting demand next.
Tradeweb Processed $61 Trillion in August. Bond Chaos Is Its Business.
When yields swing and portfolios reposition, Tradeweb collects a fee on every trade, and August’s data shows how durable that…
SoftBank’s 20% share surge bets everything on OpenAI
A record ¥1 trillion retail bond priced last week. Savers fund Son’s AI bet.
Anthropic’s IPO Delay Is the Institutional Demand Signal Nobody Wants to Name
SpaceX is about 34% below its June peak. That is the price discovery Anthropic's bankers are racing to get ahead…
OPEC+ Froze October Oil Output at 31.01M Barrels. Q4 Is Wide Open.
The first pause in six months removes a near-term supply overhang, but the group said nothing about November or December,…
Jabil Reports Sept. 24. Three Hyperscalers and $13.6B in AI Revenue Say Listen Closely.
Fiscal Q4 earnings are expected Sept. 24, and Jabil has raised its FY2026 AI revenue outlook to about $13.6B. The…
Casey’s Is About to Tell Us What $4 Gas Pays
Tuesday’s earnings cover the priciest Labor Day fuel stretch, and the math works differently than drivers think.